Neuroendocrine tumours (NETs) are rare tumours arising from cells of the nervous and endocrine systems. Since the 1990's, the use of somatostatin analogues (SSTa) imaging for NETs evaluation has allowed a better understanding of these neoplasms. Recent 68gallium labelled somatostatin analogues with higher affinity for somatostatin receptors are now available for PET/CT imaging of NETs, leading to new imaging protocols for patient care. Three new analogues (DOTATOC, DOTANOC, DOTATATE) were superior to OctreoScan®, and conventional imaging for lesion detection. In this article, recent publications on the diagnostic and care of gastroenteropancreatic (GEP) tumours, pheochromocytomas/paragangliomas (PPGLs), unknown primary tumours, medullary thyroid carcinomas (MTC), Merkel tumours and Cushing syndrome with ectopic ACTH hypersecretion are reviewed.